Cargando…

MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells

In multiple myeloma (MM), homeostasis is largely maintained by misfolded protein clearance via the proteasomal and aggresomal pathways. Histone deacetylase 6 (HDAC6) binds polyubiquitinated proteins and dynein motors and transports this protein cargo to the aggresome for further degradation. Accordi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Fang-I, Wu, Yi-Wen, Sung, Ting-Yi, Liou, Jing-Ping, Lin, Mei-Hsiang, Pan, Shiow-Lin, Yang, Chia-Ron
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465934/ https://www.ncbi.nlm.nih.gov/pubmed/31024851 http://dx.doi.org/10.3389/fonc.2019.00249

Ejemplares similares

Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells
por: Tsai, Feng-Lung, et al.
Publicado: (2023)

The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
por: Tu, Huang-Ju, et al.
Publicado: (2018)

A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo
por: Wu, Yi-Wen, et al.
Publicado: (2021)

A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin
por: Wang, Li-Ting, et al.
Publicado: (2014)

A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability in Human Cancer Cells in Vitro and in Vivo
por: Wu, Yi-Wen, et al.
Publicado: (2018)

Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
por: Chao, Min-Wu, et al.
Publicado: (2019)

Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis
por: Huang, Yen-Chia, et al.
Publicado: (2015)

Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma
por: Chen, Mei-Chuan, et al.
Publicado: (2015)

A novel action mechanism for MPT0G013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expression
por: Wang, Chih-Ya, et al.
Publicado: (2014)

The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model
por: Fan, Sheng-Jun, et al.
Publicado: (2018)

MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-γ-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells
por: Chen, Mei-Chuan, et al.
Publicado: (2019)

HDAC Inhibitor L-Carnitine and Proteasome Inhibitor Bortezomib Synergistically Exert Anti-Tumor Activity In Vitro and In Vivo
por: Huang, Hongbiao, et al.
Publicado: (2012)

TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis
por: Huang, Han-Li, et al.
Publicado: (2019)

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells
por: Chen, M-C, et al.
Publicado: (2013)

TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis: Erratum
por: Huang, Han-Li, et al.
Publicado: (2021)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
por: Lee, Sang Wu, et al.
Publicado: (2021)

An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells
por: Chao, Min-Wu, et al.
Publicado: (2017)

MPT0G066, a novel anti-mitotic drug, induces JNK-independent mitotic arrest, JNK-mediated apoptosis, and potentiates antineoplastic effect of cisplatin in ovarian cancer
por: Huang, Han-Li, et al.
Publicado: (2016)

Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo
por: Huang, Han-Lin, et al.
Publicado: (2012)

Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009
por: Hsieh, I-N, et al.
Publicado: (2014)

Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells
por: Chen, Chun-Han, et al.
Publicado: (2019)

YM155 exerts potent cytotoxic activity against quiescent (G(0)/G(1)) multiple myeloma and bortezomib resistant cells via inhibition of survivin and Mcl-1
por: Ookura, Miyuki, et al.
Publicado: (2017)

Gambogenic acid synergistically potentiates bortezomib-induced apoptosis in multiple myeloma
por: Chen, Runzhe, et al.
Publicado: (2017)

Correction: Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo
por: Huang, Han-Li, et al.
Publicado: (2012)

Optimization and Development of Selective Histone Deacetylase Inhibitor (MPT0B291)-Loaded Albumin Nanoparticles for Anticancer Therapy
por: Putri, Athika Darumas, et al.
Publicado: (2021)

Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo
por: Huang, Han-Li, et al.
Publicado: (2014)

Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat
por: Cheng, Tiewei, et al.
Publicado: (2021)

Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells
por: Kawabata, S, et al.
Publicado: (2012)

Synergistically Anti-Multiple Myeloma Effects: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib
por: Ding, Kaixi, et al.
Publicado: (2022)

Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells
por: Schrenk, Christian, et al.
Publicado: (2023)

Combining an Autophagy Inhibitor, MPT0L145, with Abemaciclib Is a New Therapeutic Strategy in GBM Treatment
por: Hsieh, Tsung-Han, et al.
Publicado: (2021)

CircRERE confers the resistance of multiple myeloma to bortezomib depending on the regulation of CD47 by exerting the sponge effect on miR-152-3p
por: Fang, Wei, et al.
Publicado: (2021)

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action
por: Imai, Yoichi, et al.
Publicado: (2019)

Targeting arginase-1 exerts antitumor effects in multiple myeloma and mitigates bortezomib-induced cardiotoxicity
por: Ramji, Kavita, et al.
Publicado: (2022)

Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression
por: Cao, Liqin, et al.
Publicado: (2022)

Histone deacetylase inhibitor MPT0B291 suppresses Glioma Growth in vitro and in vivo partially through acetylation of p53
por: Buyandelger, Batsaikhan, et al.
Publicado: (2020)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Schedule of experiment R413
por: Jarlskog, G
Publicado: (1973)

Progress report of R413
por: CERN. Geneva. Intersecting Storage-Rings Committee
Publicado: (1974)

Cannot write session to /tmp/vufind_sessions/sess_lvvfnfbjk0tbhf9kj3ndg75s7s